Data / Drug companies / Hyoscyamine sulfate
Hyoscyamine sulfate: 24 companies and 53 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Hyoscyamine sulfate is listed in the FDA National Drug Code Directory by 24 companies, with 53 products in commercial distribution. 0 of the products (0.0%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet; tablet, orally disintegrating; tablet, extended release, and the newest product started marketing on July 27, 2026.
The request: Get every company that lists hyoscyamine sulfate in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 24
- Products
- 53
- Generic (ANDA) products
- 0 (0.0%)
- Application numbers
- 0
- Routes
- Oral, Sublingual, Subcutaneous
- Brand names
- Hyosyne, Oscimin, Levsin SL, Hyoscyamine Er, NuLev, Levsin, Levbid
- openFDA record search
- api.fda.gov
Companies that list hyoscyamine sulfate
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Chartwell RX, LLC | 6 | tablet; solution | Other unapproved drugs | September 20, 2024 |
| Ani Pharmaceuticals, Inc. | 4 | tablet; tablet, orally disintegrating | Other unapproved drugs | February 15, 2024 |
| Patrin Pharma, Inc. | 4 | tablet; tablet, extended release | Other unapproved drugs | August 16, 2024 |
| Viatris Specialty LLC | 4 | tablet, orally disintegrating; tablet, chewable | Other unapproved drugs | December 1, 2008 |
| Acella Pharmaceuticals, LLC | 3 | tablet; tablet, orally disintegrating | Other unapproved drugs | May 19, 2011 |
| Bryant Ranch Prepack | 3 | tablet | Other unapproved drugs | October 1, 2018 |
| Granulation Technology, Inc. | 3 | tablet; tablet, orally disintegrating | Other unapproved drugs | July 27, 2026 |
| Westminster Pharmaceuticals, LLC | 3 | tablet; tablet, orally disintegrating | Other unapproved drugs | April 2, 2025 |
| Atlantic Biologicals Corp. | 2 | elixir | Other unapproved drugs | November 1, 1997 |
| Bryant Ranch Prepack | 2 | tablet | Other unapproved drugs | October 1, 2018 |
| Lannett Company, Inc. | 2 | elixir; solution/ drops | Other unapproved drugs | November 1, 1997 |
| Larken Laboratories, Inc. | 2 | tablet; tablet, orally disintegrating | Other unapproved drugs | August 3, 2011 |
| NCS HealthCare of Ky, LLC DBA Vangard Labs | 2 | tablet | Other unapproved drugs | February 15, 2024 |
| Northwind Health Company, LLC | 2 | tablet | Other unapproved drugs | February 6, 2023 |
| Remedyrepack Inc. | 2 | tablet | Other unapproved drugs | August 13, 2025 |
| Bpi Labs LLC | 1 | injection, solution | Other unapproved drugs | October 18, 2019 |
| Bryant Ranch Prepack | 1 | tablet | Other unapproved drugs | May 19, 2011 |
| Laser Pharmaceuticals, LLC | 1 | tablet, extended release | Other unapproved drugs | January 26, 2024 |
| Mylan Pharmaceuticals Inc. | 1 | tablet, extended release | Other unapproved drugs | May 1, 2016 |
| PD-Rx Pharmaceuticals, Inc. | 1 | tablet, orally disintegrating | Other unapproved drugs | April 16, 2026 |
| Proficient Rx LP | 1 | tablet | Other unapproved drugs | April 2, 2025 |
| QPharma, Inc. | 1 | tablet | Other unapproved drugs | May 19, 2011 |
| Redpharm Drug | 1 | tablet | Other unapproved drugs | May 19, 2011 |
| Sportpharm LLC | 1 | tablet | Other unapproved drugs | May 19, 2011 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 30 | 56.6% |
| Tablet, orally disintegrating | 9 | 17% |
| Tablet, extended release | 6 | 11.3% |
| Elixir | 4 | 7.5% |
| Solution | 1 | 1.9% |
| Tablet, chewable | 1 | 1.9% |
| Solution/ drops | 1 | 1.9% |
| Injection, solution | 1 | 1.9% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Other unapproved drugs | 53 | 100% |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.